Analysts Set Turn Therapeutics Inc. (NASDAQ:TTRX) PT at $9.00

Turn Therapeutics Inc. (NASDAQ:TTRX) has received a consensus rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.00.

Several analysts have issued reports on TTRX shares. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Wall Street Zen upgraded Turn Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th. WBB Securities reaffirmed a “sell” rating and issued a $10.00 price target on shares of Turn Therapeutics in a research note on Monday, September 14th. Finally, Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th.

Institutional Investors Weigh In On Turn Therapeutics

Several institutional investors have recently added to or reduced their stakes in TTRX. Tamar Securities LLC purchased a new position in shares of Turn Therapeutics in the fourth quarter valued at about $59,000. Bank of America Corp DE purchased a new stake in shares of Turn Therapeutics during the second quarter worth about $103,000. Jefferies Financial Group Inc. purchased a new stake in shares of Turn Therapeutics during the second quarter worth about $119,000. DDFG Inc grew its stake in shares of Turn Therapeutics by 34.9% in the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after purchasing an additional 18,246 shares during the last quarter. Finally, Bridgewater Advisors Inc. purchased a new position in Turn Therapeutics during the 2nd quarter valued at about $242,000.

Turn Therapeutics Price Performance

Shares of NASDAQ TTRX opened at $14.94 on Monday. The stock has a market capitalization of $445.06 million and a P/E ratio of -51.52. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The firm’s 50 day simple moving average is $10.20 and its two-hundred day simple moving average is $6.64. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. As a group, analysts expect that Turn Therapeutics will post -0.4 EPS for the current fiscal year.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.